KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

PubWeight™: 13.40‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMC 545207)

Published in PLoS Med on January 25, 2005

Authors

William Pao1, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus

Author Affiliations

1: Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. paow@mskcc.org

Associated clinical trials:

Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer (PROFILER) | NCT01774409

Articles citing this

(truncated to the top 100)

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82

Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A (2008) 5.08

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell (2005) 4.48

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn (2005) 4.21

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev (2006) 4.06

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.89

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene (2009) 3.86

Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80

Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 3.28

Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell (2008) 3.25

Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23

The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20

High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer (2006) 2.97

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79

Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res (2012) 2.52

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol (2008) 2.28

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res (2008) 2.28

Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One (2007) 2.25

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20

Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res (2012) 2.10

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04

The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci (2008) 2.00

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn (2008) 1.99

A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res (2010) 1.98

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J (2008) 1.96

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer (2008) 1.90

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol (2013) 1.88

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer (2007) 1.85

High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79

KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn (2009) 1.78

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn (2007) 1.77

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol (2009) 1.76

Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A (2011) 1.68

Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol (2011) 1.67

Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev Res (Phila) (2009) 1.67

Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther (2011) 1.66

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66

Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One (2011) 1.65

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal (2010) 1.64

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res (2009) 1.64

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis (2010) 1.64

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol (2011) 1.63

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) (2011) 1.61

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol (2011) 1.55

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer (2007) 1.55

EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget (2010) 1.53

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest (2011) 1.52

Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A (2008) 1.51

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer (2012) 1.49

Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest (2013) 1.49

Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47

TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res (2008) 1.44

Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol (2009) 1.44

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res (2015) 1.43

From human genome to cancer genome: the first decade. Genome Res (2013) 1.42

Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int (2016) 1.42

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol (2011) 1.42

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol (2013) 1.42

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. Clin Cancer Res (2015) 1.42

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res (2009) 1.42

Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol (2006) 1.40

Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res (2009) 1.39

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res (2011) 1.38

Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics (2006) 1.38

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract (2012) 1.34

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech (2009) 1.34

Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One (2013) 1.32

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther (2010) 1.30

Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol (2008) 1.30

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res (2015) 1.29

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer (2006) 1.29

Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One (2013) 1.29

Articles cited by this

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58

Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35

Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res (1988) 3.91

Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene (1990) 3.65

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001) 3.22

The ras oncogenes in human lung cancer. Am Rev Respir Dis (1990) 2.31

Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg (1992) 1.72

Articles by these authors

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95

Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55

Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24

Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64

Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst (2009) 5.05

Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04

Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol (2006) 4.97

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol (2004) 4.77

Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A (2003) 4.69

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37

Functional copy-number alterations in cancer. PLoS One (2008) 4.27

Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn (2005) 4.21

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev (2006) 4.06

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04

Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88

WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res (2007) 3.74

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol (2013) 3.71

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68

Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64

Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res (2011) 3.56